Physician profile
Sarah Ware
NPI 1881350387
$577.27
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $446.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $155.50 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $124.14 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $105.65 | 2022 | |
| Novo Nordisk INC | $97.65 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $15.00 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.87 | 2021 | |
| Amgen INC. | $13.57 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.29 | 2022 | |
| Ironwood Pharmaceuticals, INC | $13.29 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.79 | 2022 | |
| Amarin Pharma, INC. | $12.52 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.